CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021. The presentation will be available to registered conference… Read More..
- Company Updates Guidance for Fiscal 2021 Revenue of $64 - $69.5 Million with Adjusted Operating Loss* of ($2.5) - ($5.0) Million and Provides Guidance for Fiscal 2022 Revenue of $90-100 Million with Adjusted Operating Income* (Not Including Corporate Overhead) of Breakeven to $2.5 Million - Revenue Increased 96.9% YOY… Read More..
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO & Investor Digital Conference, being held from February 16 –… Read More..